ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity

Wu, Yaoqiang; Lin, Han; You, Xia; Guo, Taiyan; Sun, Tingting; Xu, Hao*; Fu, Xibo*哈尔滨医科大学; 中国医科大学; 1
Frontiers in Oncology2022-3-10DOI: 10.3389/fonc.2022.764923
2被引7阅读
引用收藏
分享

摘要

More than half of new cases of hepatocellular carcinoma (HCC) and associated deaths occurring annually worldwide are recorded in China. Chinese patients with HCC exhibit special characteristics in terms of etiology, leading to differences in prognosis versus Western patients. In recent years, several angiogenesis inhibitors were approved, and immune checkpoint blockers (ICBs) were recommended as second-line therapy for advanced HCC. In addition, the recent success of a combination of atezolizumab with bevacizumab signals resulted in an essential change in the first-line treatment of HCC. We investigated the characteristics of patients with HCC in China and summarized the rapidly emerging relevant clinical data, which relate to the prospects and challenges associated with the use of ICBs in this setting. We further evaluated the efficacy of ICBs in Chinese patients with HCC based on data obtained from global trials, and discussed possible factors influencing the effectiveness of ICBs in patients with HCC in China. Immunotherapy offers new options for the treatment of advanced HCC, though responses varied between patients. Currently, there is a need to discover specific biomarkers for the accurate identification of patients who would more likely benefit from immunotherapy. Furthermore, investigation of patient characteristics in different countries is necessary to provide a clinical practice basis and reference value for the diagnosis and treatment of HCC.

学科与关键词

关键词
hepatocellular carcinoma (HCC)immune checkpoint blockers (ICBs)combination immunotherapytranscatheter arterial chemoembolization (TACE)traditional Chinese medicines (TCM)
相关
加载中…
  • Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
    Yang, Yu; Sun, Juxian; Wu, Mengchao; Lau, Wan Yee; Zheng, Shusen; Wang, Xue-Hao; Chen, Xiaoping; Fan, Jia; Dong, Jiahong; Cai, Jianqiang; Chen, Minshan; Chen, Yongjun; Cheng, Zhangjun; Dai, Chaoliu; Shan, Jianzhen; Du, Cheng-You; Fang, Chihua; Hu, Heping; Ji, Zhili; Jia, Weidong; Li, Gong; Li, Jing; Li, Jiangtao; Liu, Chang; Liu, Fubao; Ma, Yong; Mao, Yilei; Niu, Zuoxing; Shen, Jie; Shi, Jie; Shi, Xuetao; Song, Wenjie; Sun, Hui-Chuan; Tan, Guang; Tao, Ran; Wang, Xiaohu; Wen, Tianfu; Wu, LiqunLiver Cancer, 2022, 11(6): 511-526.被引 9
  • Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
    Liu, Zhuoyan; Liu, Xuan; Liang, Jiaxin; Liu, Yixin; Hou, Xiaorui; Zhang, Meichuan; Li, Yongyin*; Jiang, Xiaotao*Frontiers in Immunology, 2021, 12: 765101.被引 63
  • The advanced development of molecular targeted therapy for hepatocellular carcinoma
    Yan, Tao; Yu, Lingxiang; Zhang, Ning; Peng, Caiyun; Su, Guodong; Jing, Yi; Zhang, Linzhi; Wu, Tong; Cheng, Jiamin; Guo, Qian; Shi, Xiaoliang*; Lu, Yinying*Cancer Biology & Medicine, 2022, 19(6): 802-817.被引 17
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-03-10
卷期
第 12 卷
页码
764923
DOI
10.3389/fonc.2022.764923
期刊等级
3区
成果收录
SCIE

作者

  • W

    Wu, Yaoqiang (第一作者)

  • L

    Lin, Han

    1 · harbin med univ

查看全部 7 位作者收起作者
  • Y

    You, Xia

  • G

    Guo, Taiyan

  • S

    Sun, Tingting

  • X

    Xu, Hao (通讯)

    china med univ

  • F

    Fu, Xibo (通讯)

    china med univ · liaoning canc hosp & inst

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417